Submission of Outcome of the EGM.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Astal Laboratories Limited held its Extra Ordinary General Meeting (EGM) on November 6, 2025, via video conferencing, with 24 members present. Three key items were transacted through e-voting: (1) an ordinary resolution to increase the company's Authorized Share Capital and amend the Capital Clause of the Memorandum of Association, (2) a special resolution approving the acquisition of a 100% stake in Sriven Pharmachem India Private Limited through a share swap via preferential allotment, and (3) an ordinary resolution approving a material related party transaction linked to the same acquisition. The meeting was chaired by Independent Director Dr. Radhakishore Pandrangi and concluded at 3:21 PM. Consolidated voting results will be shared with the stock exchange within 48 hours.
Shareholders should watch for the voting results within 48 hours, as the resolutions involve a capital restructuring and a potentially value-impacting acquisition of Sriven Pharmachem via share swap, which could lead to equity dilution depending on the swap ratio. The related party transaction approval suggests insiders are involved in the deal, warranting close scrutiny of the final terms.